Home › Compare › CALT vs MCD

CALT vs MCD: Dividend Comparison 2026

CALT yields 5.00% · MCD yields 2.35%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MCD wins by $50.8K in total portfolio value· pulled ahead in Year 5
10 years
CALT
CALT
● Live price
5.00%
Share price
$40.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$27.8K
Annual income
$688.45
Full CALT calculator →
MCD
McDonald's Corporation
● Live price
2.35%
Share price
$308.53
Annual div
$7.26
5Y div CAGR
42.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$78.5K
Annual income
$26,227.70
Full MCD calculator →

Portfolio growth — CALT vs MCD

📍 MCD pulled ahead of the other in Year 5

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCALTMCD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CALT + MCD cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
CALT pays
MCD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CALT
Annual income on $10K today (after 15% tax)
$425.00/yr
After 10yr DRIP, annual income (after tax)
$585.18/yr
MCD
Annual income on $10K today (after 15% tax)
$200.01/yr
After 10yr DRIP, annual income (after tax)
$22,293.55/yr
At 15% tax rate, MCD beats the other by $21,708.36/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CALT + MCD for your $10,000?

CALT: 50%MCD: 50%
100% MCD50/50100% CALT
Portfolio after 10yr
$53.2K
Annual income
$13,458.08/yr
Blended yield
25.32%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MCD right now

CALT
Analyst Ratings
5
Hold
Consensus: Hold
Price Target
$39.50
-1.3% upside vs current
Range: $39.00 — $40.00
Altman Z
8.0
Piotroski
2/9
MCD
Analyst Ratings
37
Buy
23
Hold
1
Sell
Consensus: Buy
Price Target
$351.76
+14.0% upside vs current
Range: $320.00 — $385.00
Altman Z
4.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CALT buys
0
MCD buys
0
No recent congressional trades found for CALT or MCD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCALTMCD
Forward yield5.00% ✓2.35%
Annual dividend / share$2.00$7.26 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%42.3% ✓
Portfolio after 10y$27.8K$78.5K ✓
Annual income after 10y$688.45$26,227.70 ✓
Total dividends collected$6.0K$58.5K ✓
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusHoldBuy
Analyst price target$39.50$351.76 ✓

Year-by-year: CALT vs MCD ($10,000, DRIP)

YearCALT PortfolioCALT Income/yrMCD PortfolioMCD Income/yrGap
1$11,200$500.00$10,815$334.85+$385.00 → CALT
2$12,507$523.36$11,826$491.71+$681.00 → CALT
3$13,929$546.22$13,123$730.06+$806.00 → CALT
4$15,473$568.51$14,853$1,100.07+$620.00 → CALT
5← crossover$17,146$590.20$17,257$1,690.61$111.00 → MCD
6$18,957$611.24$20,752$2,667.01$1.8K → MCD
7$20,916$631.60$26,103$4,354.83$5.2K → MCD
8$23,031$651.27$34,794$7,437.78$11.8K → MCD
9$25,314$670.22$49,926$13,461.60$24.6K → MCD
10$27,774$688.45$78,550$26,227.70$50.8K → MCD

CALT vs MCD: Complete Analysis 2026

CALT — Stock

Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was incorporated in 2004 and is headquartered in Stockholm, Sweden.

Full CALT Calculator →

MCD — Consumer Discretionary

McDonald's Corporation operates and franchises McDonald's restaurants in the United States and internationally. Its restaurants offer hamburgers and cheeseburgers, chicken sandwiches and nuggets, wraps, fries, salads, oatmeal, shakes, desserts, sundaes, soft serve cones, bakery items, soft drinks, coffee, and beverages and other beverages, as well as breakfast menu, including biscuit and bagel sandwiches, breakfast burritos, hotcakes, and other sandwiches. As of December 31, 2021, the company operated 40,031 restaurants. McDonald's Corporation was founded in 1940 and is headquartered in Chicago, Illinois.

Full MCD Calculator →
📬

Get this CALT vs MCD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CALT vs SCHDCALT vs JEPICALT vs OCALT vs KOCALT vs MAINCALT vs YUMCALT vs QSRCALT vs SBUX

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.